Regen BioPharmaRGBP 14-Day RSI is 42.08 as of Jul. 02, 2026. The stock has 7 warning signs investors should review. Among 1,423 Biotechnology companies, Regen BioPharma ranks better than 71.33% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-02), Regen BioPharma's 14-Day RSI is 42.08.
The industry rank for Regen BioPharma's 14-Day RSI or its related term are showing as below:
RGBP's 14-Day RSI is ranked better than 71.33% of 1423
companies
in the Biotechnology industry
Industry Median: 48.64
vs RGBP: 42.08
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Regen BioPharma 14-Day RSI Related Terms
RGBP vs SIGY, ENDV, CNBX: 14-Day RSI Comparison
For the Biotechnology subindustry, Regen BioPharma's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regen BioPharma 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regen BioPharma's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Regen BioPharma's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regen BioPharma (RGBP) has a 14-Day RSI of 42.08 as of Jul. 02, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Regen BioPharma and its competitors. According to the industry distribution chart, Regen BioPharma ranks #408 out of 1423 companies in the Biotechnology industry, placing it in the top 28.7%.
Is Regen BioPharma's 14-Day RSI too high?
Regen BioPharma's current 14-Day RSI is 42.08. The Biotechnology industry median 14-Day RSI is 48.64. Regen BioPharma's value of 42.08 is 13.5% below this industry median. Based on the distribution chart, Regen BioPharma ranks #408 out of 1423 companies in the Biotechnology industry, which is above the industry midpoint.
How does Regen BioPharma's 14-Day RSI compare to SIGY and ENDV?
According to the Biotechnology industry distribution chart, Regen BioPharma ranks #408 out of 1423 companies for 14-Day RSI. This puts Regen BioPharma in the upper half of its industry. The industry median 14-Day RSI is 48.64. Regen BioPharma's value of 42.08 is 13.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 48.64, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regen BioPharma's current 14-Day RSI of 42.08 is 13.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Regen BioPharma and its competitors. For the Biotechnology industry, the median 14-Day RSI is 48.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regen BioPharma's current 14-Day RSI is 42.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99.5% below its estimated fair value. The current 14-Day RSI is 42.08 and 13.5% below the Biotechnology industry median of 48.64. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current 14-Day RSI is 42.08 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGBP has been successfully added to your